LifeStance Health Group (NASDAQ:LFST) Given New $16.00 Price Target at BTIG Research

LifeStance Health Group (NASDAQ:LFST) had its price target raised by BTIG Research from $15.00 to $16.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms also recently commented on LFST. Canaccord Genuity Group upped their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings restated a “hold (c-)” rating on shares of LifeStance Health Group in a research report on Wednesday, May 27th. Finally, KeyCorp boosted their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Moderate Buy” and a consensus target price of $11.62.

LifeStance Health Group Price Performance

NASDAQ:LFST opened at $10.84 on Friday. LifeStance Health Group has a 12-month low of $3.90 and a 12-month high of $11.76. The firm has a market capitalization of $4.20 billion, a price-to-earnings ratio of 83.39 and a beta of 1.14. The stock’s 50 day moving average price is $9.95 and its two-hundred day moving average price is $8.05. The company has a quick ratio of 1.48, a current ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. During the same period in the previous year, the company posted ($0.01) EPS. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, analysts anticipate that LifeStance Health Group will post 0.12 earnings per share for the current year.

Insider Buying and Selling

In other LifeStance Health Group news, Director Darren M. Black sold 5,899,661 shares of LifeStance Health Group stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the sale, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. The trade was a 20.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Eric Shuey sold 243,362 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the sale, the director directly owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This represents a 21.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 7,612,394 shares of company stock valued at $62,938,451. 3.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On LifeStance Health Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LFST. Assetmark Inc. boosted its holdings in shares of LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after purchasing an additional 1,367 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of LifeStance Health Group by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after acquiring an additional 1,966 shares during the last quarter. Vident Advisory LLC lifted its holdings in shares of LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after acquiring an additional 2,447 shares during the last quarter. Xponance LLC boosted its stake in shares of LifeStance Health Group by 26.4% in the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after purchasing an additional 2,745 shares in the last quarter. Finally, Diversified Trust Co grew its holdings in shares of LifeStance Health Group by 14.8% during the 1st quarter. Diversified Trust Co now owns 21,532 shares of the company’s stock valued at $137,000 after purchasing an additional 2,770 shares during the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG raises price target: BTIG Research raised its LFST price target from $15 to $16 and initiated a “buy” rating, implying substantial potential appreciation from the referenced $10.84 price. Benzinga price target report
• Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, exceeding the $0.03 consensus estimate, compared with a $0.01 loss in the year-earlier quarter. Revenue rose 26.1% year over year to approximately $435.4 million, ahead of the $414.6 million analyst forecast. LifeStance Q2 earnings report
• Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% and the clinician base grew 11% to 8,542, supporting the company’s growth outlook. LifeStance financial results release
• Positive Sentiment: Full-year outlook raised: Management increased 2026 revenue guidance to $1.685 billion-$1.725 billion, Center Margin guidance to $570 million-$594 million and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue is projected at $420 million-$440 million, above the $417.7 million consensus estimate.
• Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million of common-stock repurchases, potentially supporting per-share results and signaling management confidence in the company’s valuation.
• Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, but reported $259.0 million of net long-term debt.
• Negative Sentiment: Insider selling remains a risk: Recent disclosed insider activity has consisted entirely of sales, including substantial transactions by TPG-related entities and company executives. Continued selling could temper investor enthusiasm despite the strong operating results.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.